Cellular senescence—the irreversible arrest of cell proliferation accompanied by a pro-inflammatory secretory phenotype—has emerged as a foundational driver of chronic organ deterioration and tissue degeneration. In this comprehensive clinical review, we examine the molecular pathways of senescent cell clearance and emerging senotherapeutic interventions.
The Senescence-Associated Secretory Phenotype (SASP)
While acute senescence serves an essential physiological role in tumor suppression and wound healing, the chronic accumulation of non-dividing senescent cells severely disrupts the microenvironment. Senescent cells continuously secrete a toxic cocktail termed the Senescence-Associated Secretory Phenotype (SASP), comprised of:
- Pro-inflammatory Cytokines: Interleukin-6 (IL-6), Interleukin-1β (IL-1β), and TNF-alpha.
- Chemokines: MCP-1 (CCL2) and IL-8 (CXCL8), which sustain chronic sterile inflammation.
- Matrix Metalloproteinases (MMPs): MMP-1, MMP-3, and MMP-13, which degrade extracellular matrix scaffolding and compromise tissue tensile strength.
🔬 Clinical Insight: The Bystander Effect
SASP factors actively induce paracrine senescence in adjacent healthy parenchymal cells via reactive oxygen species (ROS) and chemokine signaling, amplifying local tissue dysfunction exponentially.
Senolytic Compounds vs. Senomorphic Interventions
Modern translational biogerontology classifies anti-senescence pharmacotherapies into two distinct operational categories:
| Therapeutic Class | Primary Mechanism | Representative Candidates | Target Tissues |
|---|---|---|---|
| Senolytics | Selective apoptosis induction via SCAP pathway inhibition | Dasatinib + Quercetin (D+Q), Fisetin, Navitoclax (ABT-263) | Adipose, vascular endothelium, pulmonary parenchyma |
| Senomorphics | Suppression of SASP cytokine transcription without cell death | Rapamycin (mTORC1 inhibitors), Metformin, Apigenin | Systemic microenvironment, immune compartments |
Clinical Safety & Intermittent Dosing Strategies
Because senescent cell pro-survival pathways (SCAPs) are only intermittently required for clearance, pulsed senolytic regimens (e.g., administered once monthly or quarterly) effectively purge the senescent cell burden without the toxicity associated with continuous receptor occupancy.